Biological
RSVpreF vaccine
RSVpreF vaccine is a biological therapy with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
1(20%)
Results Posted
50%(2 trials)
Phase Distribution
Ph phase_3
3
60%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(4)
Detailed Status
Completed4
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 33 (100.0%)
Trials by Status
completed480%
active_not_recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
completed
SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTS
NCT06482099
completedphase_3
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea
NCT06593587
active_not_recruiting
SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER
NCT06546800
completedphase_3
A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants
NCT06325657
completedphase_3
Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age
NCT05301322
Clinical Trials (5)
Showing 5 of 5 trials
NCT06482099
SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTS
NCT06593587Phase 3
A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea
NCT06546800
SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER
NCT06325657Phase 3
A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants
NCT05301322Phase 3
Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5